CHICAGO, June 3, 2016 /PRNewswire/ --
Angiogenesis is a hallmark of many cancers and a key target in the development of novel therapies. Similarly, angiogenesis is also involved in the inflammatory mechanisms of many chronic diseases. Magnetic Resonance Imaging (MRI) represents an imaging methodology of choice to assess [micro-] vascularization and blood perfusion.
At the annual meeting of American Society of Clinical Oncology (ASCO), Image Analysis, the medical expert company, will be presenting a new methodology for quantitative assessment of tumour response based on the changes in vascularisation and blood perfusion, which has been implemented in early phase trials, specifically to address the pseudo-progression challenge and early understanding of the treatment response.
The latest work has shown that the derived pharmacodynamics imaging biomarkers provide a better insight and understanding, as well as evidence and predictive value, of the physiological impact of novel compound in oncology clinical trials.
This new methodology for clinical trial design enables consistent, reliable, and reproducible computation of the quantitative endpoints across different imaging platforms, clinical settings and sites, as well as across various time points.
ASCO, one of the world's largest professional meetings focused on oncology research and treatment. Over 30,000 professionals will join in Chicago to learn more about this year's theme, "The Future of Patient-Centered Care and Research".
About Image Analysis Group, the portfolio company of RBV Capital created backed RVC
IMAGE ANALYSIS GROUP is an expert imaging clinical research organization, supporting the design and management of clinical trials, where imaging provides critical evidence of the novel compound safety and efficacy. The company brings together the state-of-the art cloud based systems for trial data management, patented methodologies for quantitative assessment of treatment efficacy and advisory services to enable bio-pharmaceutical clients to gain the benefits of early objective decision making on treatment efficacy from utilizing advanced imaging techniques in their trials.
For further information or to schedule a meeting, contact:
Dr Olga Kubassova
CEO, Image Analysis Group
T: + 44-207-630-9926
SOURCE Image Analysis Group